Bio-Rad Laboratories Inc
Company Profile
Business description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Contact
1000 Alfred Nobel Drive
HerculesCA94547
USAT: +1 510 724-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
7,450
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
Lithium’s latest drop and what it means for ASX investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,995.70 | 5.50 | 0.06% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 24,950.60 | 181.69 | -0.72% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 67,436.77 | 1,204.59 | 1.82% |
| NZX 50 Index | 13,691.46 | 35.43 | 0.26% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,811.20 | 4.70 | 0.05% |
| SSE Composite Index | 3,877.52 | 13.15 | 0.34% |